Managing Bone Health in Metastatic Breast Cancer
1 Visninger
• 07/03/23
0
0
Indlejre
administrator
Abonnenter
Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).
To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge
Vis mere
Facebook kommentarer
SORT BY-
Topkommentarer
-
Seneste kommentarer